Abstract

Background -  Among 195 known RHCE alleles, 10 have evolved to form hybrid RHCE-D-CE alleles encoding aberrant RhCE proteins lacking CE antigen expression. The resulting D-- phenotype predisposes to anti-Hro alloimmunization (anti-Rh17). Although hybrid alleles may appear identical at the mRNA level, distinct breakpoint configurations can result in diverse D phenotypes or Rh antigens. We determined the molecular structure of a D-- phenotype. An unrelated RHD allele, DMA  had been observed once without serology. We tested Rh antigen densities.

Materials and methods - Genomic DNA and cDNA were analyzed using a combination of molecular techniques and commercial red cell genotyping assays targeting the RHD and RHCE genes. A flow cytometric method was developed to quantify RhAG antigen expression. Red cell antigen densities were determined for RhAG and RhD in the D-- and DMA/DAU3 samples serologically.

Results - Nucleotide sequencing of the RHCE gene and its cDNA identified a homozygous CE-D(2–9)-CE hybrid allele in an individual of Afghan origin. The 5′ and 3′ breakpoint regions included 131 and 4,287 nucleotides. The new allele was linked in a haplotype to the normal RHD allele (RHD*01). Quantitative flow cytometry demonstrated antigen densities of 92,297 RhD and 52,907 RhAG molecules per red cell for the D-- sample (12,465 RhD and 117,871 RhAG for DMA/DAU3).

Discussion - We describe the breakpoint regions of a Ce–D(2–9)–Ce allele that encoded a D-- phenotype. Our results underscore the importance of breakpoint characterization for identifying clinically relevant RH variants and advancing personalized transfusion medicine. The second DMA observation, in trans to a DAU3 allele, aligned with a weak D phenotype for DMA.

Downloads

Authors

Kshitij Srivastava - Department of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, MD, United States of America https://orcid.org/0000-0002-3658-0815

Caroline Ballard Dixon - Department of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda

Marina Ursula Bueno - Department of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, MD, United States of America https://orcid.org/0009-0004-6968-9544

Katharina Schallmoser - Department for Transfusion Medicine, Paracelsus Medical University of Salzburg, Salzburg, Austria https://orcid.org/0000-0002-7204-0058

Lydia Gruener - Department for Transfusion Medicine, Paracelsus Medical University of Salzburg, Salzburg, Austria https://orcid.org/0009-0001-0194-3735

Willy Albert Flegel - Department of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, MD, United States of America https://orcid.org/0000-0002-1631-7198

  • Abstract viewed - 35 times
  • pdf downloaded - 9 times